Valbenazine (VBZ) and deutetrabenazine (DTBZ) were approved by the FDA for the treatment of TD in 2017 (Kim, 2017; Cummings et al., 2018) Both drugs, which are based on tetrabenazine (TBZ) pharmacology, block the action of VMAT2 (Dorfman and Jimenez-Shahed, 2021). This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.